Federal regulators are telling drugmakers to remove label warnings about potential suicidal thoughts and behaviors from their blockbuster weight-loss drugs. The U.S. Food and Drug Administration on Tuesday advised the action for Novo Nordisk's Wegovy and Saxenda and Eli Lilly's Zepbound. Agency officials say a comprehensive review “found no increased risk” related to suicide among users of the GLP-1 drugs used to treat obesity. A preliminary review in January 2024 had shown no link, but FDA officials said they could not rule out that “a small risk may exist.” The new analysis puts those concerns to rest.
